Research Topics
| Raffaele BrunoSummaryAffiliation: University of Pavia Country: Italy Publications
| Collaborators
|
Detail Information
Publications
Natural history of compensated viral cirrhosis in a cohort of patients with HIV infectionRaffaele Bruno
Division of Infectious and Tropical Diseases, Instituto di Ricerca e Cura a Carattere Scientifico, San Matteo Hospital, University of Pavia, Italy
J Acquir Immune Defic Syndr 46:297-303. 2007..This study was designed to investigate the incidence and type of liver-related complications and mortality in coinfected cirrhotic patients...- Pharmacodynamics of peginterferon alpha-2a and peginterferon alpha-2b in interferon-naïve patients with chronic hepatitis C: a randomized, controlled studyR Bruno
Division of Infectious and Tropical Diseases, IRCCS San Matteo Hospital, University of Pavia, Pavia, Italy
Aliment Pharmacol Ther 26:369-76. 2007..Peginterferon alpha-2a and alpha-2b, the two commercially available pegylated interferons, have different pharmacokinetic properties that produce differing abilities to suppress replication of the hepatitis C virus... - Correlation between FIB4, liver stiffness and metabolic parameters in patients with HIV and hepatitis C virus co-infectionRaffaele Bruno
Division of Infectious and Tropical Diseases, Foundation IRCCS San Matteo Hospital, University of Pavia, Pavia, Italy
Dig Liver Dis 43:575-8. 2011..Aims of this study were to analyse the association of two non-invasive liver fibrosis evaluation methods, liver stiffness measurement and FIB4, and their correlation with metabolic parameters... - Hepatotoxicity and antiretroviral therapy with protease inhibitors: A reviewR Bruno
Division of Infectious and Tropical Disease, IRCCS S Matteo Hospital, University of Pavia, 27100 Pavia, Italy
Dig Liver Dis 38:363-73. 2006.... - Management of hepatocellular carcinoma in human immunodeficiency virus-infected patientsRaffaele Bruno
Division of Infectious and Tropical Diseases, IRCCS San Matteo Hospital, University of Pavia, Pavia, Italy
J Hepatol 44:S146-50. 2006..Prevention of hepatitis and cirrhosis are key goals in reducing the impact of HCC. Numerous issues in HCC prevention, diagnosis, and management still remain to be resolved through large-scale, randomized clinical trials... - Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled studyRaffaele Bruno
Division of Infectious and Tropical Diseases, IRCCS San Matteo Hospital, University of Pavia, Pavia, Italy
Antivir Ther 9:491-7. 2004..Larger-scale studies assessing both viral kinetics and sustained virological responses are needed to confirm these observations... - Area-under-the-curve for peginterferon alpha-2a and peginterferon alpha-2b is not related to body weight in treatment-naive patients with chronic hepatitis CRaffaele Bruno
Division of Infectious and Tropical Diseases, IRCCS San Matteo Hospital, University of Pavia, Pavia, Italy
Antivir Ther 10:201-5. 2005..8%). Thus, there appears to be no rationale for a body-weight dosing regimen for peginterferon alpha-2a, and such dosing does not achieve more consistent AUC measurements in patients receiving peginterferon alpha-2b... - Overview on the incidence and the characteristics of HIV-related opportunistic infections and neoplasms of the heart: impact of highly active antiretroviral therapyRaffaele Bruno
Division of Infectious and Tropical Diseases, IRCCS San Matteo Hospital, Pavia, Italy
AIDS 17:S83-7. 2003..This finding points out the need of improving our knowledge about the pathogenesis, diagnosis and treatment of this kind of complication... - Fast relapse and high drop out rate of 48 weeks daily interferon monotherapy in HIV-infected patients with chronic hepatitis CRaffaele Bruno
Division of Infectious and Tropical Disease IRCCS San Matteo Hospital, University of Pavia, Pavia, Italy
BMC Infect Dis 2:17. 2002..In HIV patients the use of this combination therapy may induce drug interactions, and reduces the adherence to HAART. The aim of this study is to evaluate safety and efficacy of a 48 weeks daily dose IFN schedule... - Management of hepatitis C in human immunodeficiency virus-infected patientsR Bruno
Division of Infectious and Tropical Diseases, IRCCS S Matteo Hospital, University of Pavia, Italy
Dig Liver Dis 34:452-9. 2002..Since management of co-infected patients is complex a multidisciplinary approach is needed in order to facilitate care and help patients to achieve a positive outcome... - Prevalence and histologic features of transfusion transmitted virus and hepatitis C virus coinfection in a group of HIV patientsR Bruno
Division of Infectious and Tropical Diseases, University of Pavia, IRCCS S Matteo, Pavia, Italy
Dig Liver Dis 32:617-20. 2000..A recently identified DNA transfusion-transmitted virus has been associated with post-transfusion non-A to G hepatitis... - Comparison of the plasma pharmacokinetics of lamivudine during twice and once daily administration in patients with HIVR Bruno
Division of Infectious and Tropical Diseases, IRCCS San Matteo Hospital, University of Pavia, Italy
Clin Pharmacokinet 40:695-700. 2001..To compare the plasma pharmacokinetics of lamivudine 150mg twice daily and 300mg once daily in patients with HIV-1 infection... - Pathogenesis of liver damage in HCV-HIV patientsRaffaele Bruno
Division of Infectious and Tropical Diseases, Fondazione IRCCS San Matteo Hospital, University of Pavia, Pavia, Italy
AIDS Rev 10:15-24. 2008.... - Challenges for hepatitis C patients coinfected with HIVRaffaele Bruno
Hepatology Outpatients Unit, IRCCS S. Matteo Hospital-University of Pavia, Via Taramelli 5, 27100 Pavia, Italy
Am Clin Lab 21:26-31. 2002 - Host factors affecting the outcome of treatment of hepatitis CRaffaele Bruno
Division of Infectious and Tropical Diseases, IRCCS San Matteo Hospital-University of Pavia, Pavia, Italy
Rev Gastroenterol Disord 4:S3-7. 2004..Results of a head-to-head comparison have demonstrated the possibility that, in cases of dose reduction, levels of peginterferon alfa-2a could remain above the limit of detection, whereas those of peginterferon alfa-2b might not... - HCV chronic hepatitis in patients with HIV: clinical management issuesRaffaele Bruno
Division of Infectious and Tropical Disease, IRCCS S. Matteo Hospital, University of Pavia, Italy
Am J Gastroenterol 97:1598-606. 2002..Liver transplantation in HIV patients is currently under evaluation, but should become the rescue therapy for HIV patients with end stage liver disease... - Evaluation of the risk factors associated with lipodystrophy development in a cohort of HIV-positive patientsEleng Seminari
Infectious Disease Department, IRCCS, Policlinico S. Matteo Hospital, University of Pavia, Pavia, Italy
Antivir Ther 7:175-80. 2002..Patients with lipoatrophy had had a greater exposure to stavudine... - Hepatotoxicity and nelfinavir: a meta-analysisRaffaele Bruno
Division of Infectious and Tropical Diseases, Istituto di Ricovero e Cura a Carattere Scientifico San Mateo Hospital--University of Pavia, Italy
Clin Gastroenterol Hepatol 3:482-8. 2005..CONCLUSIONS: In conclusion, these data provide support for the conclusion that differences in the potential for hepatotoxicity do exist among the commercially available protease inhibitors... - Dissociation of serum and liver hepatitis C virus RNA levels in patients coinfected with human immunodeficiency virus and treated with antiretroviral drugsMilena Furione
Servizio di Virologia, Laboratori di Ricerca, Area Infettivologica, , Via Taramelli 5, 27100 Pavia, Italy
J Clin Microbiol 42:3012-6. 2004.... - Coarse vs. fine needle aspiration biopsy for the assessment of diffuse liver disease from hepatitis C virus-related chronic hepatitisEnrico Brunetti
Division of Infectious and Tropical Diseases, IRCSS S Matteo, University of Pavia, Via Taramelli 5, 27100 Pavia, Italy
J Hepatol 40:501-6. 2004..As fine needles (FN) do not require anaesthesia, are used over a wider range of coagulation values and allow multiple passes, we compared the diagnostic yield of FN vs. CN biopsies... - Hepatitis C virus infection and antiviral treatment in marginal zone lymphomasLuca Arcaini
Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Italy
Curr Clin Pharmacol 5:74-81. 2010.... - Forthcoming challenges in the management of direct-acting antiviral agents (DAAs) for hepatitis CRaffaele Bruno
Department of Infectious Diseases, Foundation IRCCS San Matteo Hospital University of Pavia, Pavia, Italy
Dig Liver Dis 43:337-44. 2011..The lesson of HIV therapy, provide a compelling case for the exploration of combinations of direct-acting antiviral agents... - gp120 modulates the biology of human hepatic stellate cells: a link between HIV infection and liver fibrogenesisRaffaele Bruno
Division of Infectious and Tropical Diseases, University of Pavia Foundation, IRCCS, San Matteo Hospital, Pavia, Italy
Gut 59:513-20. 2010..In this study, an investigation was carried out to determine whether gp120, an HIV envelope protein, modulates the biology of human hepatic stellate cells (HSCs), key cell types in the pathogenesis of fibrosis... - Distinct mutational drug resistance profiles of HIV-1 RNA in plasma and culture isolates of patients receiving antiretroviral therapyMarizia Debiaggi
Department of Microbiology, University of Pavia School of Medicine and IRCCS Policlinico San Matteo, Pavia, Italy
Intervirology 45:52-5. 2002..These results emphasize the need for standardization and clinical laboratory use of phenotypic assays that avoid extensive cocultivation... - Quantification of HIV-1 proviral DNA in patients with undetectable plasma viremia over long-term highly active antiretroviral therapyM Debiaggi
Department of Microbiology, University of Pavia, IRCCS Policlinico San Matteo, via Brambilla, 74 27100, Pavia, Italy
Int J Infect Dis 4:187-93. 2000..To assess the prognostic role of proviral DNA in peripheral blood mononuclear cells (PBMC) of patients with undetectable viremia over long-term highly active antiretroviral therapy (HAART)... - Subcutaneous 'lipoma-like' B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALTM Paulli
Department of Human Pathology, University of Pavia, Pavia, Italy
Ann Oncol 21:1189-95. 2010..Molecular analysis of immunoglobulin heavy chain (IGH) gene rearrangement and FISH investigations for t(11;18)(q21;q21) and t(14;18)(q32;q21) were carried out in nine patients... - Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomasLuca Arcaini
Divison of Hematology, Fondazione IRCCS Policlinico S Matteo, University of Pavia, Viale Golgi 19, Pavia, Italy
Am J Hematol 85:46-50. 2010..This could be a limit to the application of immunochemotherapy programs. HCV+ lymphomas represent a distinct clinical subset of NHL that deserves specific clinical approach to limit liver toxicity and ameliorate survival... - Viral excretion in cervicovaginal secretions of HIV-1-infected women receiving antiretroviral therapyM Debiaggi
Department of Microbiology, University of Pavia, Italy
Eur J Clin Microbiol Infect Dis 20:91-6. 2001.... - Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALTL Arcaini
Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Italy
Ann Oncol 18:346-50. 2007.... - Comparison of IFN-alpha 2b with or without ribavirin for treatment of chronic hepatitis C in HIV-positive patients infected with hepatitis C virus genotype 3aGiulia Morsica
AIDS 18:1080-2. 2004 - The pavia consensus statementPaul A Volberding
University of California, San Francisco, USA
AIDS 17:S170-9. 2003 - Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis: an emerging issueRaffaele Bruno
J Acquir Immune Defic Syndr 30:535-6. 2002 - Clinical experiences with interferon as monotherapy or in combination with ribavirin in patients co-infected with HIV and HCVMassimo Puoti
Clinica di Malattie Infettive e Tropicali Università degli Studi di Brescia AO Spedali Civili, Brescia, Italy
HIV Clin Trials 3:324-32. 2002..The search for the perfect treatment continues... - Mitochondrial toxicity in HIV-HCV coinfection: It depends on the choice of antiretroviral drugs?Raffaele Bruno
Hepatology 35:500-1. 2002 - Hepatitis B virus co-infection in human immunodeficiency virus-infected subjectsMassimo Puoti
Clinica di Malattie Infecttive e Tropicali, Università degli studi de Brescia, AO Spedali Civili dei Brescia
AIDS Rev 4:27-35. 2002..Highly Active Anti-Hepatitis B Therapy will probably soon come of age... - Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus WorkshopGiampiero Carosi
Department of Infectious Disease, University of Brescia, Brescia, Italy
AIDS Rev 7:161-7. 2005.... - Prevalence of metabolic syndrome among HIV patientsCarmine Gazzaruso
Diabetes Care 25:1253-4. 2002 - Comment to the editorial: Liver biopsy in HIV-infected patients with chronic hepatitis C: pros and cons, by Vincent Soriano and Javier GarcÃa-SamaniegoMassimo Puoti
Department of Infectious Diseases, University of Brescia--AO Spedali Civili, Brescia, Italy
HIV Clin Trials 3:419-20. 2002 - Didanosine-ribavirin combination: synergistic combination in vitro, but high potential risk of toxicity in vivoRaffaele Bruno
AIDS 17:2674-5. 2003 - Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcomeMassimo Puoti
FClinica di Malattie Infettive, Università degli Studi di Brescia AO Spedali Civili, Brescia, Clinica di Malattie Infettive e Tropicali, Madrid, Spain
AIDS 18:2285-93. 2004..Hepatocellular carcinoma (HCC) is an increasing cause of mortality in HIV-seropositive individuals. The aim of the study was to compare the main features of HCC in HIV-seropositive individuals with those in to HIV-negative patients... - The management of hepatitis B virus/HIV-1 co-infected patients starting their first HAART regimen. Treating two infections for the price of one drug?Massimo Puoti
Institute of Infectious and Tropical Diseases, Spedali Civili, University of Brescia, Brescia, Italy
Antivir Ther 9:811-7. 2004..3; -131.7, P=0.003] and a significantly reduced risk of liver-related morbidity/mortality [Relative hazard (RH)=0.07; 95% CI: 0.01-0.38, P=0.002] than those starting a lamivudine sparing-regimen... - Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patientsJacob Nattermann
Department of Internal Medicine I, University of Bonn, Bonn, Germany
Hepatology 46:1016-25. 2007..CONCLUSION: Response rates to HCV-specific treatment are higher in HCV/HIV-positive patients carrying the IL-6 HP genotype, which might be because of IL-6 mediated STAT3 activation... - Could tenofovir modify the model end-stage liver disease (MELD) score in patients with end-stage liver disease eligible for liver transplantation?Raffaele Bruno
J Acquir Immune Defic Syndr 45:123. 2007 - Natural history of chronic hepatitis B in co-infected patientsMassimo Puoti
Clinica di Malattie Infettive e Tropicali, AO Spedali Civili, Universita di Brescia, P zzle Spedali Civili 1, I 25123 Brescia, Italy
J Hepatol 44:S65-70. 2006.... - Comments on the review 'Care of patients with hepatitis C and HIV co-infection' by Soriano et alRaffaele Bruno
AIDS 18:2101-2; author reply 2102-3. 2004 - Hepatitis B virus genotype distribution in HIV-1 coinfected patientsGianguglielmo Zehender
Gastroenterology 125:1559-60; author reply 1660. 2003 - Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndromeCarmine Gazzaruso
Internal Medicine Unit, Cardiovascular Prevention Clinic ASTRA, IRCCS Maugeri Foundation Hospital, Scientific Institute of Pavia, Italy
J Hypertens 21:1377-82. 2003.... - Rapid hepatitis B virus-DNA decay in co-infected HIV-hepatitis B virus 'e-minus' patients with YMDD mutations after 4 weeks of tenofovir therapyRaffaele Bruno
AIDS 17:783-4. 2003 - High prevalence of metabolic syndrome among HIV-infected patients: link with the cardiovascular riskRaffaele Bruno
J Acquir Immune Defic Syndr 31:363-5. 2002 - Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfectionGuenther Schmutz
Center for HIV and Hepatogastroenterology, Grafenberger Allee 128a, 40237 Duesseldorf, Germany
AIDS 20:1951-4. 2006..Over a median treatment period of 116 weeks tenofovir was as effective as tenofovir plus lamivudine. Longer treatment periods may be needed to evaluate potential benefits of first-line combination therapy for chronic hepatitis B...